Check out this article from ALS News Today on Retrotope's rapid enrollment of its ongoing Phase 2 trial of RT001 for the treatment of amyotrophic lateral sclerosis (ALS). The piece offers great context on the ongoing study, as well as how the mechanism of action for RT001 may be able to help patients with neurodegenerative diseases such as ALS.

We appreciate TRICALS helping raise awareness of the initiation of our Phase 2 clinical study of RT001 in ALS in Europe. A special thank you to the world-class clinical investigators who are making this trial possible.

News of Retrotope's recent rare pediatric disease designation for RT001 in INAD was included in AAO's "Week in Review" roundup of key ophthalmic news. Did you know Retrotope also has a preclinical program in dry AMD? An IND filing for RT011 in this indication is expected in 2021.

The team at Friedreich’s Ataxia News helped spread the word about Retrotope's recent rare pediatric disease designation and Fast Track designation for RT001 in FA. Our pivotal Phase 2/3 trial of RT001 in FA is fully enrolled and we expect data from the study by the end of 2021.

Anil Kumar, Retrotope’s president and chief business officer, gave a corporate presentation as part of the 2021 BIO CEO & Investor Digital Conference. The presentation highlighted a busy year ahead for Retrotope with multiple key data readouts planned for its broad clinical-stage pipeline.

A matchstick animation illustrating the concept of the LPO in lipid membranes, and the role of D-PUFAs in inhibiting the chain reaction.

Dr. Mark Midei, Retrotope's Chief of Medical Affairs, and Susan Walther, Director of Patient Engagement at Friedreich's Ataxia Research Alliance (FARA), recorded a video about Retrotope’s Friedreich’s ataxia study.

Dr. Charles Cantor, co-founder and executive director of Retrotope, Inc., presenting on GoldLab Symposium 2019.

Mikhail Shchepinov, Chief Scientific Officer at Retrotope, Inc., presenting at Undoing Aging 2019 in Berlin.